Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $100.00 price target on by analysts at Leerink Partners.
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe [Yahoo! Finance]
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Bank of America Corporation from $86.00 to $97.00. They now have a "buy" rating on the stock.
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)